Page 1472 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 81 Mantle Cell Lymphoma 1308.e1

REFERENCES an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol
16(12):3803–3809, 1998.
1. Vose JM: Mantle cell lymphoma: 2013 Update on diagnosis, risk- 18. Romaguera JE, Khouri IF, Kantarjian HM, et al: Untreated aggressive
stratification, and clinical management. Am J Hematol 88(12):1082– mantle cell lymphoma: results with intensive chemotherapy without
1088, 2013. stem cell transplant in elderly patients. Leuk Lymphoma 39(1–2):77–85,
2. Jares P, Colomer D, Campo E: Genetic and molecular pathogenesis of 2000.
mantle cell lymphoma: perspectives for new targeted therapeutics. Nat 19. Gianni AM, Magni M, Martelli M, et al: Long-term remission in mantle
Rev Cancer 7(10):750–762, 2007. cell lymphoma following high-dose sequential chemotherapy and in
3. Swerdlow SH, Campo E, Harris NL, et al: WHO Classification of Tumours vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood
of Haematopoietic and Lymphoid Tissues. Primary mediastinal (thymic) large 102(2):749–755, 2003.
B-cell lymphoma, Lyon, France, 2008, IARC Press, pp 250–251. 20. de Guibert S, Jaccard A, Bernard M, et al: Rituximab and DHAP followed
4. Howard OM, Gribben JG, Neuberg DS, et al: Rituximab and CHOP by intensive therapy with autologous stem-cell transplantation as first-
induction therapy for newly diagnosed mantle-cell lymphoma: molecular line therapy for mantle cell lymphoma. Haematologica 91(3):425–426,
complete responses are not predictive of progression-free survival. J Clin 2006.
Oncol 20(5):1288–1294, 2002. 21. Epner EM, Unger J, Miller T, et al: A Multi Center Trial of
5. Forstpointner R, Dreyling M, Repp R, et al: The addition of rituximab hyperCVAD+Rituxan in Patients with Newly Diagnosed Mantle Cell
to a combination of fludarabine, cyclophosphamide, mitoxantrone Lymphoma. ASH Annual Meeting Abstracts 110(11):387, 2007.
(FCM) significantly increases the response rate and prolongs survival 22. Ritchie DS, Seymour JF, Grigg AP, et al: The hyper-CVAD-rituximab
as compared with FCM alone in patients with relapsed and refractory chemotherapy programme followed by high-dose busulfan, melphalan
follicular and mantle cell lymphomas: results of a prospective random- and autologous stem cell transplantation produces excellent event-free
ized study of the German Low-Grade Lymphoma Study Group. Blood survival in patients with previously untreated mantle cell lymphoma.
104(10):3064–3071, 2004. Ann Hematol 86(2):101–105, 2007.
6. Lenz G, Dreyling M, Hoster E, et al: Immunochemotherapy with ritux- 23. Dreger P, Rieger M, Seyfarth B, et al: Rituximab-augmented myeloabla-
imab and cyclophosphamide, doxorubicin, vincristine, and prednisone tion for first-line autologous stem cell transplantation for mantle cell
significantly improves response and time to treatment failure, but not lymphoma: effects on molecular response and clinical outcome. Haema-
long-term outcome in patients with previously untreated mantle cell tologica 92(1):42–49, 2007.
lymphoma: results of a prospective randomized trial of the German Low 24. Damon LE, Johnson JL, Niedzwiecki D, et al: Immunochemotherapy
Grade Lymphoma Study Group (GLSG). J Clin Oncol 23(9):1984–1992, and autologous stem-cell transplantation for untreated patients with
2005. mantle-cell lymphoma: CALGB 59909. J Clin Oncol 27(36):6101–6108,
7. Herold M, Haas A, Doerken B, et al: Immunochemotherapy (R-MCP) in 2009.
advanced mantle cell lymphoma is not superior to chemotherapy (MCP) 25. van ‘t Veer MB, de Jong D, MacKenzie M, et al: High-dose Ara-C
alone: 50 months up date of the OSHO phase III study (OSHO#39). and beam with autograft rescue in R-CHOP responsive mantle cell
Ann Oncol 19:iv86, 2008. Abstract O12. lymphoma patients. Br J Haematol 144(4):524–530, 2009.
8. Ruan J, Martin P, Furman RR, et al: Bortezomib plus CHOP-rituximab 26. Gressin R, Caulet-Maugendre S, Deconinck E, et al: Evaluation of the
for previously untreated diffuse large B-cell lymphoma and mantle cell (R)VAD+C regimen for the treatment of newly diagnosed mantle cell
lymphoma. J Clin Oncol 29(6):690–697, 2011. lymphoma. Combined results of two prospective phase II trials from the
9. Spurgeon SE, Pindyck T, Okada C, et al: Cladribine plus rituximab is French GOELAMS group. Haematologica 95(8):1350–1357, 2010.
an effective therapy for newly diagnosed mantle cell lymphoma. Leuk 27. Romaguera JE, Fayad LE, Feng L, et al: Ten-year follow-up after intense
Lymphoma 52(8):1488–1494, 2011. chemoimmunotherapy with Rituximab-HyperCVAD alternating with
10. Grant C, Neelapu SS, Kwak LW, et al: Eleven-Year Follow-up of Idiotype Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem
Vaccine and DA-EPOCH-Rituximab in Untreated Mantle Cell Lym- cell transplantation in patients with untreated aggressive mantle cell
phoma: Correlation of Survival with Idiotype Immune Response. ASH lymphoma. Br J Haematol 150(2):200–208, 2010.
Annual Meeting Abstracts 118(21):2707, 2011. 28. Chang JE, Peterson C, Choi S, et al: VcR-CVAD induction chemo-
11. Kluin-Nelemans HC, Hoster E, Hermine O, et al: Treatment of older therapy followed by maintenance rituximab in mantle cell lymphoma:
patients with mantle-cell lymphoma. N Engl J Med 367(6):520–531, a Wisconsin Oncology Network study. Br J Haematol 155(2):190–197,
2012. 2011.
12. Smith MR, Li H, Gordon L, et al: Phase II study of rituximab plus 29. Merli F, Luminari S, Ilariucci F, et al: Rituximab plus HyperCVAD
cyclophosphamide, doxorubicin, vincristine, and prednisone immu- alternating with high dose cytarabine and methotrexate for the initial
nochemotherapy followed by yttrium-90-ibritumomab tiuxetan in treatment of patients with mantle cell lymphoma, a multicentre trial
untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group from Gruppo Italiano Studio Linfomi. Br J Haematol 156(3):346–353,
Study E1499. J Clin Oncol 30(25):3119–3126, 2012. 2012.
13. Dunleavy K, Grant C, Hessler J, et al: Bortezomib + DA-EPOCH-R 30. Geisler CH, Kolstad A, Laurell A, et al: Nordic MCL2 trial update:
Induction Therapy Followed by Maintenance Bortezomib Versus six-year follow-up after intensive immunochemotherapy for untreated
Observation in Newly Diagnosed Mantle Cell Lymphoma. ASH Annual mantle cell lymphoma followed by BEAM or BEAC + autologous
Meeting Abstracts 120(21):3672, 2012. stem-cell support: still very long survival but late relapses do occur. Br J
14. Rummel MJ, Niederle N, Maschmeyer G, et al: Bendamustine plus Haematol 158(3):355–362, 2012.
rituximab versus CHOP plus rituximab as first-line treatment for patients 31. Ahmadi T, McQuade J, Porter D, et al: Potential prolongation of PFS
with indolent and mantle-cell lymphomas: an open-label, multicentre, in mantle cell lymphoma after R-HyperCVAD: auto-SCT consolidation
randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203–1210, or rituximab maintenance. Bone Marrow Transplant 47(8):1082–1086,
2013. 2012.
15. Visco C, Finotto S, Zambello R, et al: Combination of rituximab, benda- 32. Hermine O, Hoster E, Walewski J, et al: Alternating Courses of 3x
mustine, and cytarabine for patients with mantle-cell non-Hodgkin lym- CHOP and 3x DHAP Plus Rituximab Followed by a High Dose
phoma ineligible for intensive regimens or autologous transplantation. J ARA-C Containing Myeloablative Regimen and Autologous Stem Cell
Clin Oncol 31(11):1442–1449, 2013. Transplantation (ASCT) Increases Overall Survival When Compared to
16. Flinn IW, van der Jagt R, Kahl BS, et al: Randomized trial of 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Radio-
bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of chemotherapy and ASCT in Mantle Cell Lymphoma: Final Analysis
indolent NHL or MCL: the BRIGHT study. Blood 123(19):2944–2952, of the MCL Younger Trial of the European Mantle Cell Lymphoma
2014. Network (MCL net). ASH Annual Meeting Abstracts 120(21):151, 2012.
17. Khouri IF, Romaguera J, Kantarjian H, et al: Hyper-CVAD and high- 33. Delarue R, Haioun C, Ribrag V, et al: CHOP and DHAP plus ritux-
dose methotrexate/cytarabine followed by stem-cell transplantation: imab followed by autologous stem cell transplantation in mantle cell